Innovative Cancer Testing MiRNA Scientific offers a pioneering non-invasive liquid biopsy urine test for prostate cancer, providing a unique molecular-level detection and monitoring solution that could be attractive to healthcare providers seeking advanced diagnostic tools.

Growing Precision Healthcare Stack With a proprietary miR Disease Management Platform focused on value-based cancer care, there is potential for expanding diagnostic capabilities or developing additional tests that can address other urological or systemic cancers within existing customer networks.

Expanding Market Reach Positioned in the biotech industry with revenue between 10 and 25 million dollars, MiRNA Scientific has opportunities to partner with larger healthcare institutions or leverage collaborations to scale its testing services and increase market penetration.

Technology Adoption Utilizing a modern tech stack, including Google Analytics and Insightly CRM, suggests readiness for targeted outreach and data-driven sales strategies, enabling personalized engagement with prospective clients such as hospitals, clinics, and research centers.

Potential for Funding Growth While currently not specified, pursuing additional funding rounds could accelerate product development, support commercialization, and allow for broader clinical validation efforts, creating further sales opportunities across the oncology diagnostics sector.